Literature DB >> 23913691

Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.

David E Ehmann1, Haris Jahic, Philip L Ross, Rong-Fang Gu, Jun Hu, Thomas F Durand-Réville, Sushmita Lahiri, Jason Thresher, Stephania Livchak, Ning Gao, Tiffany Palmer, Grant K Walkup, Stewart L Fisher.   

Abstract

Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 10(1) m(-1)s(-1) for OXA-10 to 1.0 × 10(5) for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed.

Entities:  

Keywords:  Antibiotics; Drug Discovery; Enzyme Inhibitors; Enzyme Kinetics; Mass Spectrometry (MS)

Mesh:

Substances:

Year:  2013        PMID: 23913691      PMCID: PMC3784710          DOI: 10.1074/jbc.M113.485979

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.

Authors:  Thérèse Stachyra; Marie-Claude Péchereau; Jean-Michel Bruneau; Monique Claudon; Jean-Marie Frère; Christine Miossec; Kenneth Coleman; Michael T Black
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

Authors:  A Walkty; M DeCorby; P R S Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 3.  The behavior and significance of slow-binding enzyme inhibitors.

Authors:  J F Morrison; C T Walsh
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1988

Review 4.  Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.

Authors:  Neil Gupta; Brandi M Limbago; Jean B Patel; Alexander J Kallen
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

5.  Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Kerri M Smith; Yan Xu; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 6.  New β-lactam antibiotics and β-lactamase inhibitors.

Authors:  Karen Bush; Mark J Macielag
Journal:  Expert Opin Ther Pat       Date:  2010-10       Impact factor: 6.674

7.  In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.

Authors:  Shazad Mushtaq; Marina Warner; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2010-08-26       Impact factor: 5.790

8.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

9.  Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.

Authors:  Krisztina M Papp-Wallace; Christopher R Bethel; Anne M Distler; Courtney Kasuboski; Magdalena Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

Review 10.  New β-lactam-β-lactamase inhibitor combinations in clinical development.

Authors:  David M Shlaes
Journal:  Ann N Y Acad Sci       Date:  2013-01       Impact factor: 5.691

View more
  143 in total

1.  Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Elise T Zeiser; Nozomi Ohuchi; Maria F Mojica; Julian A Gatta; Monica Falleni; Delfina Tosi; Elisa Borghi; Marisa L Winkler; Brigid M Wilson; John J LiPuma; Michiyoshi Nukaga; Robert A Bonomo
Journal:  ACS Infect Dis       Date:  2017-03-30       Impact factor: 5.084

2.  In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Boudewijn L M de Jonge; Meredith A Hackel; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.

Authors:  Krisztina M Papp-Wallace; Marisa L Winkler; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

5.  Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.

Authors:  Krisztina M Papp-Wallace; Nhu Q Nguyen; Michael R Jacobs; Christopher R Bethel; Melissa D Barnes; Vijay Kumar; Saralee Bajaksouzian; Susan D Rudin; Philip N Rather; Satish Bhavsar; Tadiparthi Ravikumar; Prasad K Deshpande; Vijay Patil; Ravindra Yeole; Sachin S Bhagwat; Mahesh V Patel; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

6.  Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

7.  Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.

Authors:  S D Lahiri; M R Johnstone; P L Ross; R E McLaughlin; N B Olivier; R A Alm
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

8.  In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

Review 9.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

Review 10.  Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing Carbapenemases.

Authors:  Navaneeth Narayanan; Linda Johnson; Conan MacDougall
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.